Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion type Assertion NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_head.
- NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion description "[The crude odds ratios (OR) and 95% confidence intervals (95% CI) associated with the RAD51 GC/CC genotype frequency was OR, 1.10; 95% CI, 0.80-1.41 for breast cancer and OR, 1.22; 95% CI, 0.92-1.62 for ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_provenance.
- NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion evidence source_evidence_literature NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_provenance.
- NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion SIO_000772 15734952 NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_provenance.
- NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion wasDerivedFrom befree-20140225 NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_provenance.
- NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_assertion wasGeneratedBy ECO_0000203 NP621928.RAvC_JFXtp4Ft7h3mIMAuycZOkZhDx3GRfpATjUEXudfI130_provenance.